Rischin D, Porceddu S, Day F, Brungs DP, Christie H, Jackson JE et al, for the C-POST Trial Investigators.
N Engl J Med 2025; 393: 774-785.
The study included 415 patients followed for a median of 24 months. Adjuvant Cemiplimab improved two-year disease-free survival to 87.1 per cent from 64.1 per cent with placebo, P<0.001.
Comment: Immunotherapy wins again, this time for high-risk skin cancer.
.png)
.jpg){kind=logo}
